Shocker: Samantha quits acting for some time; stops signing new projects
She will head to the US for myositis treatment
Sridevi S (BOMBAY TIMES; July 6, 2023)

Samantha Ruth Prabhu has decided to take a six-month break from films to focus on her health. The actress has been battling myositis, an autoimmune disease, which can cause intense muscle pain and inflammation.

Squashing rumours that implied she had returned advance payments to film producers to take this break, a source close to her informs us, “Samantha is currently shooting for a film with Vijay Deverakonda and has another four days of shoot left. She has also nearly finished work on her web series that also stars Varun Dhawan. However, health is a priority now. She has been advised to rest well and avoid stress by her doctors, and is heading to the US for further treatment. She is just ensuring that she finishes all her film commitments before heading to the US, there has been no return of advance payments because she has not signed anything new. She will be back in six months or sooner. It all depends on how she feels after treatment.”
----------------------------------
Sugandha Rawal (HINDUSTAN TIMES; July 6, 2023)

After wrapping up Indian version of Citadel, actor Samantha is going to take a step back from acting for at least a year. She will focus on her health and undergo treatment for myositis in the US during this period.

“A few months back, Samantha decided that she would take a break from acting and was just waiting to wrap up her projects — Kushi and Citadel (alongside actors Vijay Deverakonda and Varun Dhawan, respectively). She is not signing any projects currently,” says a source close to the actor, calling reports of her returning money to producers for the projects she had signed, “assumption and exaggeration”.

In October 2022, the 36-year-old revealed her myositis diagnosis and took a six-month break. “She was in the middle of shooting for Kushi when she fell ill. Now, she must go for the main treatment and therapy,” shares the source.